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Introduction
Juvenile idiopathic arthritis (JIA) is the most common
children rheumatic disease. This term includes different
clinical subtypes that do not have the same presentation,
prognosis and therapeutic response. Therefore some stu-
dies review this classification, and proposed other cri-
teria as antinuclear antibodies (ANA), age of beginning
or uveitis. Our objective was to look for an association
between different clinical subtypes of JIA and some sin-
gle nucleotide polymorphism (SNP), which have already
been identify in JIA and other auto-immune diseases.
Method
We performed a retrospective, monocentric study. Chil-
dren were classified according to the International Lea-
gue of Associations for Rheumatology (ILAR)
classification. Polyarticular and systemic forms, and
patients who required biologics were defined as severe.
DNA from patients was extracted from a blood sample,
and was placed on a FTA elute card. Four SNP in four
genes were analysed (TGF-B codon 25 rs1800471,
TRAF-1 C5 rs10818488, STAT 4 rs7574865, et PTPN22
rs2476601). A Fisher test was performed to analyze the
association between those SNP and the different clinical
sub types of JIA.
Results
101 children with JIA were included. Oligoarticular form
was the most frequent (68 patients, mean age 4.87 years
old (YO)). Polyarticular (FR + and FR -) and enthesitis
related arthritis (ERA) forms were less frequent (mean
age 5.16 and 11 YO respectively). 18 children developed
an uveitis, especially when AAN are positive (14
associated with oligoarticular form). 38 were treated
with TNF antagonist (29.4% of oligoarticular, 42.1% of
polyarticular and 100% of systemic forms). Genotype
CC of PTPN22 seems to be more frequent in oligoarti-
cular form, but this association is not significant
(p=0.12). However, in ANA-positive patients, this asso-
ciation is significant with oligoarticular form, compared
to polyarticular JIA (p<0.05). In oligoarticular forms,
genotype AA of TRAF1C5 seems to be associated with
the risk of uveitis, but this association is not significant.
We did not find association between those SNP and
other clinical subtype, disease severity or age of
beginning.
Conclusion
We could not find a significant association between
those genetic markers and the different clinical subtype
of JIA, but a trend for an association between oligoarti-
cular form and genotype CC of this SNP of PTPN22.
We are going to try to confirm this association includ-
ing more children in this study.
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